Heterogeneity in MYC-induced mammary tumors contributes to escape from oncogene dependence

Oncogene

Volumn 31, Issue 20, 2012, Pages 2545-2554

  Leung, J Y ^a   Andrechek, E R ^b   Cardiff, R D ^c   Nevins, J R ^a  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

^b MICHIGAN STATE UNIVERSITY   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

cancer; EMT; mammary; mouse; MYC

Indexed keywords

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BREAST CANCER; BREAST TUMOR; CANCER CELL; CELL HETEROGENEITY; CELL INVASION; CELL MIGRATION; CONTROLLED STUDY; EPITHELIAL MESENCHYMAL TRANSITION; GENE ACTIVITY; GENE EXPRESSION; GENETIC HETEROGENEITY; GENOME ANALYSIS; MOUSE; NONHUMAN; ONCOGENE MYC; PHENOTYPE; PRIORITY JOURNAL; TRANSGENIC MOUSE; TUMOR REGRESSION;

ANIMALS; BREAST NEOPLASMS; CELL TRANSFORMATION, NEOPLASTIC; DISEASE MODELS, ANIMAL; EPITHELIAL-MESENCHYMAL TRANSITION; FEMALE; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; GENES, RAS; HUMANS; MAMMARY NEOPLASMS, EXPERIMENTAL; MICE; MICE, TRANSGENIC; NEOPLASTIC STEM CELLS; PROTO-ONCOGENE PROTEINS C-MYC; TRANSFORMING GROWTH FACTOR ALPHA; TRANSFORMING GROWTH FACTOR BETA;

MUS MUSCULUS;

EID: 84861395041     PISSN: 09509232     EISSN: 14765594     Source Type: Journal    
DOI: 10.1038/onc.2011.433     Document Type: Article

References (31)

1. Al-Hajj M, Wicha MS, Benito-Hernandez A, Morrison SJ, Clarke MF. (2003). Prospective identification of tumorigenic breast cancer cells. Proc Natl Acad Sci USA 100: 3983-3988. (Pubitemid 36418143)
2. Andrechek ER, Cardiff RD, Chang JT, Gatza ML, Acharya CR, Potti A et al. (2009). Genetic heterogeneity of Myc-induced mammary tumors reflecting diverse phenotypes including metastatic potential. Proc Natl Acad Sci USA 106: 16387-16392.
3. Bild AH, Yao G, Chang JT, Wang Q, Potti A, Chasse D et al. (2006). Oncogenic pathway signatures in human cancers as a guide to targeted therapies. Nature 439: 353-357. (Pubitemid 43128862)
4. Boxer RB, Jang JW, Sintasath L, Chodosh LA. (2004). Lack of sustained regression of c-MYC-induced mammary adenocarcinomas following brief or prolonged MYC inactivation. Cancer Cell 6: 577-586. (Pubitemid 40017701)
5. Campbell LL, Polyak K. (2007). Breast tumor heterogeneity: cancer stem cells or clonal evolution? Cell Cycle 6: 2332-2338. (Pubitemid 350058682)
6. Cardiff RD. (2010). The pathology of EMT in mouse mammary tumorigenesis. J Mammary Gland Biol Neoplasia 15: 225-233.
7. Carvalho CM, Chang J, Lucas JE, Nevins JR, Wang Q, West M. (2008). High-dimensional sparse factor modeling: applications in gene expression genomics. J Am Stat Assoc 103: 1438-1456.
8. Creighton CJ, Li X, Landis M, Dixon JM, Neumeister VM, Sjolund A et al. (2009). Residual breast cancers after conventional therapy display mesenchymal as well as tumor-initiating features. Proc Natl Acad Sci USA 106: 13820-13825.
9. D'Cruz CM, Gunther EJ, Boxer RB, Hartman JL, Sintasath L, Moody SE et al. (2001). c-MYC induces mammary tumorigenesis by means of a preferred pathway involving spontaneous Kras2 mutations. Nat Med 7: 235-239. (Pubitemid 32148492)
10. Damonte P, Gregg JP, Borowsky AD, Keister BA, Cardiff RD. (2007). EMT tumorigenesis in the mouse mammary gland. Lab Invest 87: 1218-1226. (Pubitemid 350126707)
11. Diehn M, Cho RW, Clarke MF. (2009). Therapeutic implications of the cancer stem cell hypothesis. Semin Radiat Oncol 19: 78-86.
12. Ding L, Ellis MJ, Li S, Larson DE, Chen K, Wallis JW et al. (2010). Genome remodelling in a basal-like breast cancer metastasis and xenograft. Nature 464: 999-1005.
13. Ding L, Getz G, Wheeler DA, Mardis ER, McLellan MD, Cibulskis K et al. (2008). Somatic mutations affect key pathways in lung adenocarcinoma. Nature 455: 1069-1075.
14. Gatza ML, Lucas JE, Barry WT, Kim JW, Wang Q, Crawford MD et al. (2010). A pathway-based classification of human breast cancer. Proc Natl Acad Sci USA 107: 6994-6999.
15. Herschkowitz JI, Simin K, Weigman VJ, Mikaelian I, Usary J, Hu Z et al. (2007). Identification of conserved gene expression features between murine mammary carcinoma models and human breast tumors. Genome Biol 8: R76.
16. Huang E, Ishida S, Pittman J, Dressman H, Bild A, Kloos M et al. (2003). Gene expression phenotypic models that predict the activity of oncogenic pathways. Nat Genet 34: 226-230. (Pubitemid 36666937)
17. Iseri O, Kars MD, Arpaci F, Atalay C, Pak I, Gunduz U. (2011). Drug resistant MCF-7 cells exhibit epithelial-mesenchymal transition gene expression pattern. Biomed Pharmacother 65: 40-45.
18. Jain M, Arvanitis C, Chu K, Dewey W, Leonhardt E, Trinh M et al. (2002). Sustained loss of a neoplastic phenotype by brief inactivation of MYC. Science 297: 102-104. (Pubitemid 34743102)
19. Lucas J, Carvalho C, West M. (2009). A bayesian analysis strategy for cross-study translation of gene expression biomarkers. Stat Appl Genet Mol Biol 8: 1-26 (Article 11).
20. Mani SA, Guo W, Liao MJ, Eaton EN, Ayyanan A, Zhou AY et al. (2008). The epithelial-mesenchymal transition generates cells with properties of stem cells. Cell 133: 704-715. (Pubitemid 351636299)
21. Moody SE, Perez D, Pan TC, Sarkisian CJ, Portocarrero CP, Sterner CJ et al. (2005). The transcriptional repressor Snail promotes mammary tumor recurrence. Cancer Cell 8: 197-209. (Pubitemid 41317591)
22. Mullighan CG, Goorha S, Radtke I, Miller CB, Coustan-Smith E, Dalton JD et al. (2007). Genome-wide analysis of genetic alterations in acute lymphoblastic leukaemia. Nature 446: 758-764. (Pubitemid 46582031)
23. Nicolini A, Ferrari P, Fini M, Borsari V, Fallahi P, Antonelli A et al. (2010). Stem cells: their role in breast cancer development and resistance to treatment. Curr Pharml Biotechnol 12: 196-205.
24. Pelengaris S, Khan M, Evan GI. (2002). Suppression of Myc-induced apoptosis in beta cells exposes multiple oncogenic properties of Myc and triggers carcinogenic progression. Cell 109: 321-334. (Pubitemid 34606875)
25. Podsypanina K, Politi K, Beverly LJ, Varmus HE. (2008). Oncogene cooperation in tumor maintenance and tumor recurrence in mouse mammary tumors induced by Myc and mutant Kras. Proc Natl Acad Sci USA 105: 5242-5247. (Pubitemid 351738541)
26. Radaelli E, Damonte P, Cardiff RD. (2009). Epithelial-mesenchymal transition in mouse mammary tumorigenesis. Future Oncol 5: 1113-1127.
27. Shachaf CM, Kopelman AM, Arvanitis C, Karlsson A, Beer S, Mandl S et al. (2004). MYC inactivation uncovers pluripotent differentiation and tumour dormancy in hepatocellular cancer. Nature 431: 1112-1117. (Pubitemid 39472236)
28. Sjoblom T, Jones S, Wood LD, Parsons DW, Lin J, Barber TD et al. (2006). The consensus coding sequences of human breast and colorectal cancers. Science 314: 268-274. (Pubitemid 44571966)
29. Thiery JP. (2002). Epithelial-mesenchymal transitions in tumour progression. Nat Rev Cancer 2: 442-454.
30. Thiery JP, Acloque H, Huang RY, Nieto MA. (2009). Epithelialmesenchymal transitions in development and disease. Cell 139: 871-890.
31. Weir BA, Woo MS, Getz G, Perner S, Ding L, Beroukhim R et al. (2007). Characterizing the cancer genome in lung adenocarcinoma. Nature 450: 893-898. (Pubitemid 350231325)